The three human TACC genes encode a family of proteins that are suspected to play a role in carcinogenesis. Their function is not precisely known; a Xenopus TACC protein called Maskin is involved in translational control, while the Drosophila D-TACC associates with microtubules and centrosomes. We have characterized the human TACC1 gene and its products. The TACC1 gene is located in region p12 of chromosome 8; its mRNA is ubiquitously expressed and encodes a protein with an apparent molecular mass of 125 kDa, which is cytoplasmic and mainly perinuclear. We show that TACC1 mRNA gene expression is down-regulated in various types of tumors. Using immunohistochemistry of tumor tissue-microarrays and sections, we confirm that the level of TACC1 protein is down-regulated in breast cancer. Finally, using the two-hybrid screen in yeast, GST pull-downs and co-immunoprecipitations, we identified two potential binding partners for TACC1, LSM7 and SmG. They constitute a conserved subfamily of Smlike small proteins that associate with U6 snRNPs and play a role in several aspects of mRNA processing. We speculate that down-regulation of TACC1 may alter the control of mRNA homeostasis in polarized cells and participates in the oncogenic processes.
Introduction
Genes and mechanisms that participate in mammary carcinogenesis are numerous and not well identified or characterized. Several genes from the chromosomal region 8p11 -21 seem to play a role in breast cancer.
The short arm of chromosome 8 is a site of frequent genetic alterations in several types of human cancers, including breast and other gynecologic carcinomas. These alterations include amplification of oncogenes such as FGFR1 in around 15% of cases (Ugolini et al., 1999) , deletions of tumor suppressor genes (TSG) of unknown identity (Ade´laı¨de et al., 1998; Ugolini et al., 1999; Pribill et al., 2001) , and in one case translocation resulting in the fusion of the NRG1 gene on 8p to the DOC4 gene from 11q13 (Wang et al., 1999) . We previously conducted a series of expression studies using various cDNA arrays. Based on the differential expression assay of chromosome 8p11 -21 genes, we identified SFRP1 and TACC1 genes, whose mRNA are reduced or absent in breast carcinomas (Ugolini et al., 1999 (Ugolini et al., , 2001 .
TACC1 (Still et al., 1999a) belongs to a family of three paralogous genes (Popovici et al., 2001 ) that also includes TACC2/AZU1/ECTACC (Chen et al., 2000; Pu et al., 2001) and TACC3 (Still et al., 1999b) , and has an ortholog in fly, tacc, located on chromosome 3R of the Drosophila genome (Gergely et al., 2000b) . TACC1 was first identified as a potential oncogene; it is sometimes included in the amplification of the 8p12 region in breast cancers and can transform fibroblasts (Still et al., 1999a) . TACC2 was identified by differential display strategies used to compare different stages of transformation of mammary epithelial cells (Chen et al., 2000) or to isolate upregulated genes from erythropoietin-stimulated endothelial cells (Pu et al., 2001) . In the former study, TACC2 appears as a suppressor of growth. TACC3 was initially identified in the databases (Still et al., 1999b) . From these early analyses, it is difficult to conclude on the exact role of TACC genes in carcinogenesis.
Clues about the function of the TACC proteins in physiological conditions have come from different studies. The tacc gene in Drosophila encodes D-TACC, a centrosomal protein required for normal spindle function in the early embryo (Gergely et al., 2000b) ; it interacts with the microtubule-associated msps/ XMAP215/ch-TOG protein to regulate microtubule behavior (Gergely et al., 2000a,b; Cullen and Ohkura, 2001 ; Lee et al., 2001; Theurkauf, 2001) . In Xenopus, a TACC protein called Maskin associates with the 3'UTR-CPE binding protein to regulate eIF-4E control of translation and oocyte maturation (Stebbins-Boaz et al., 1999) ; CPEB and Maskin are present on the mitotic apparatus of animal pole blastomeres in embryos (Groisman et al., 2000) . Thus, TACC proteins are microtubule-associated proteins that could regulate RNAs specifically located near spindles and centrosomes. In the mouse, TACC3 associates with ARNT, an arylhydrocarbon receptor-nuclear translocator protein (Sadek et al., 2000) . ARNT is a transcriptional regulator of the bHLH-PAS family that dimerizes with a number of partners, thus playing a central role in development and in several cellular processes such as detoxification and hypoxia-induced responses.
While it is too early to propose a single, integrative view of the various studies on TACC proteins, it may nevertheless be thought that alterations of TACC genes may disturb important regulations and participate to carcinogenesis. In this study, we have investigated TACC1 expression in breast cancer and gathered clues about its function. We have shown that breast cancers frequently express low levels of TACC1 protein, we have characterized TACC1 localization in human cells and identified binding partners of TACC1 that are highly suggestive of its function.
Results

Characterization of the TACC1 locus and mRNA
The exon -intron organization of the human TACC1 locus was assembled by searching for TACC1 genomic sequences in databases (http://ensembl.ebi.ac.uk/) and is shown in Figure 1a . The TACC1 gene contains 13 putative exons of various length spanning ca. 50 kb of genomic DNA. A full-length cDNA of 7758 bp encoding human TACC1 was found in databases (GenBank: AF049910) (Figure 1b) . The deduced amino-acid sequence of the TACC1 protein (TACC1l, see below) contains an open-reading frame of 805 amino-acid residues. TACC1l contains two types of motifs, a coiled-coil motif at the C-terminus, and two so-called SPAZ (serine and proline rich AZU-1) motifs (Chen et al., 2000) at the N-terminus (Figure 1c) . Two potential nuclear localization signals are also present.
TACC1 coding sequence was also subjected to BLASTN searches with dbEST database (http:// www.ncbi.nlm.nih.gov/BLAST/). Most of the clones retrieved were located in the 3' non coding region of the gene. Four cDNA clones were located in the 5' coding region of TACC1 cDNA (qh26c10, ql62e12, zw32e05, zb77b03) and represented a spliced form of the TACC1 transcript (we named TACC1s), which differs from the full length cDNA by the lack of exons 2 and 3 that codes for the SPAZ region of the TACC1l protein (Figure 1b,c) . The putative TACC1s protein contains 418 amino-acid residues.
Hybridization of a TACC1 probe to human adult multiple-tissue Northern blots identified a ubiquitously expressed transcript of 7.7 kb (Figure 2a ). We screened a series of human mammary carcinoma cell lines for the presence of TACC1 mRNA. Expression of the 7.7 kb transcript was found at various levels in the different cell lines (Figure 2b ). An additional transcript of 5 kb was also detected in some cell lines. It may correspond to TACC1s; the presence of the TACC1s spliced form in some cell lines was confirmed by RT -PCR assays of mRNA from mammary gland HME-1 cells (not shown) using specific oligonucleotide primers (see Figure 1b) .
Expression of the TACC1 proteins was studied in mammary carcinoma cell lines by Western blot analysis (Figure 2c ). Anti-TACC1-N and anti-SPAZ1 antibodies were obtained by immunization of rabbits with peptides from N-terminus or SPAZ1 motif, respectively (see Materials and methods). A commercial anti-TACC1 was also used. Proteins of 125 and 130 kDa were detected by the three antibodies in most cell lines, except in HeLa where only the 130 kDa band was seen ( Figure 2c ). The anti-SPAZ1 and commercial antibodies detected only the 130 and 125 kDa bands, whereas the anti-TACC1-N detected an additional band of 85 kDa. This band was detected in cell lysates obtained with RIPA, a strong detergent which extracts proteins from the nucleus, but weakly or not when lysis was done with NP40, a milder detergent. As shown by the reactivity with three different antibodies, the 125 kDa band corresponds to the TACC1l protein; the 130 kDa is likely to correspond to a posttranslationally modified form, possibly a phosphorylated form of TACC1l (see Figure 6d ). The 85 kDa band was observed by other authors (Gergely et al., 2000b) . We detected it only with the anti-TACC-N antibody which is the only antibody to be directed against a peptide outside the SPAZ region. The p85 TACC1 protein thus does not contain the SPAZ region and could be coded by TACC1s, or by another, unidentified type of spliced isoform. As already noted by others, the apparent molecular mass of the TACC proteins, including the fly protein (Gergely et al., 2000b) is much higher than the predicted one. It could be due to conformational structures created by the SPAZ and coiled-coil motifs. This would be true also for TACC1s.
Subcellular localization of TACC1 proteins
To further characterize TACC1, we determined its subcellular localization. Affinity-purified TACC1-N antibody was used in indirect immunofluorescence studies on transfected and non-transfected HeLa cells. Preimmune rabbit serum showed no specific reactivity in these studies (data not shown). In all the cells examined, TACC1 reactivity was observed within the cell cytoplasm; it was especially concentrated in the perinuclear area (Figure 3 ). Endogenous TACC1 (Figure 3a -c, c') was also found in the nucleus, in large subnuclear dots. These dots may correspond to nucleolar sites as seen with differential interference contrast image (data not shown). In HeLa cells transfected by either TACC1l (Figure 3d -f) or TACC1 in breast cancer N Conte et al TACC1s (Figure 3g -i, i'), the pattern of TACC1 reactivity in the perinuclear region was similar to that of non transfected cells but no protein was detected in the nucleus.
Alteration of TACC1 mRNA expression profiles in human cancers
We explored the status of TACC1 mRNA in human cancers. We first hybridized a commercial 'cancer profiling array' with a TACC1 probe. A total of 241 couples of various tumors and corresponding normal tissues were surveyed. As seen in Figure 4a , variations in mRNA signals were observed in tumors of breast, uterus, colon, ovary, lung and rectum but much less in stomach, kidney and thyroid cancers. Completely different variations were observed with a different, non TACC1 probe (not shown). After quantification, in 53 breast cancers, TACC1 expression was found higher (more than 1.5 times) in the normal sample as compared to the tumoral counterpart in 42 cases (79.2%), including the three cases with metastases; it was higher in the tumoral sample in seven cases (13.2%), including the single case of medullary carcinoma; in four cases there was no difference. The same increase in the normal vs tumoral ratios were observed for the 21 lung (85.7%), 15 ovary (93.3%) and 44 uterus (75%) cases.
To further explore the status of TACC1 in human cancer, we studied the expression of TACC1 mRNA in a series of 61 consecutive sporadic breast carcinomas by Northern blot (Figure 4b ). Of these, 39 showed an altered TACC1 expression as compared to normal breast: TACC1 was significantly underexpressed (more than a log) in 18 tumors and undetectable in 21 tumors (Figure 4c ).
Alteration of TACC1 protein expression in breast carcinomas
We next studied the expression of the TACC1 protein in a series of 57 breast tumor and 10 normal breast samples deposited in a tissue microarray Kallioniemi et al., 2001) . To allow internal comparison, we selected a series that contained relatively similar tumors of poor prognosis from women treated with anthracyclin-based adjuvant chemotherapy. Figure 5a shows an example of the results. The expression of TACC1 was observed in all normal breast tissue samples. It was found in 38 out of 57 tumors (69%) and absent in 19.
To determine more precisely the level and distribution of the TACC1 protein in breast tumor cells, samples from normal breast tissue and 48 sporadic primary breast carcinomas were subjected to immu- (Figure 5d ). Various staining patterns were observed in the tumoral tissues, either cytoplasmic only, or both cytoplasmic and nuclear. In the cytoplasm, TACC1 immunoreactivity was mostly found around the nucleus, in agreement with the pattern observed in immunofluorescence ( Figure 5c ). These experiments show that the TACC1 protein is down-regulated in around one-third of breast tumors. No correlation between TACC1 immunoreactivity and any of the histoclinical parameters was observed.
Identification of TACC1-interacting partners and phosphorylation
In an effort to define the molecular complex associated with TACC1, we used the two-hybrid system in yeast to isolate potential TACC1 partners. We screened a human mammary gland cDNA expression library with the 805 amino-acid residues of human TACC1l fused to the Gal4-binding domain. We isolated 10 cDNA clones. Eight encoded the 103 amino-acids of the LSM7 protein and two encoded the 76 amino-acids of the snRNP Sm protein G. The LSM7 gene maps on chromosome arm 19p and SmG (Herman et al., 1995) is encoded by the SNRPG gene (OMIM603542) on chromosome arm 1q. Both LSM7 and SmG are Sm-like proteins. They are related to the yeast Sm small nuclear ribonucleoproteins (snRNPs). The Sm/LSM proteins associate with small nuclear RNA to form the core of snRNPs required in a large variety of RNA maturation processes, most notably in pre-mRNA splicing and mRNA degradation, and in telomere formation Tharun et al., 2000) . To further document the interaction of TACC1 with these potential partners, we produced GST fusion proteins that were used in pull-down experiments ( Figure 6a ). Both GST-LSM7 and GST-SmG fusion proteins were able to precipitate TACC1l ( Figure 6a ) and TACC1s (data not shown) proteins. Next, proteins from Cos-1 cells cotransfected by HAtagged TACC1l with myc-tagged LSM7 or myctagged SmG were immunoprecipitated with either anti-myc or anti-TACC1-C antibody and Western blotted. In both cases, blotting with the anti-HA antibody revealed TACC1l protein and blotting with the myc antibody revealed LSM7 or SmG (Figure 6b ) confirming the interactions. Proteins from Cos-1 cells cotransfected with myc-tagged TACC1s and myctagged LSM7 or myc-tagged SmG were immunoprecipitated by anti-TACC1-C antibody and Western blotted. Blotting with anti-myc antibody revealed LSM7 or SmG (Figure 6c ). Both GST pull-down and co-immunoprecipitation results were highly reproducible.
Finally we wanted to determine if TACC1 proteins were phosphorylated and performed an in vitro kinase assay (Figure 6d ). Immunoprecipitation of TACC1 proteins showed that TACC1l was heavily phosphorylated whereas TACC1s was not.
Discussion
The TACC are regulators of cell functions which are beginning to be unravelled. Their activities have been investigated from at least three aspects, their role in cell transformation, their function in RNA processing, evidenced in Xenopus, and their role as centrosomal proteins, particularly studied in Drosophila. In this study, we have examined the status of human TACC1 in carcinomas, especially breast cancer and looked for a lead to its function.
The potential role of TACC1 in human breast cancer
We showed that the TACC1 gene is ubiquitously expressed and codes for two putative protein isoforms with coiled-coil motifs, i.e. an a superhelix (Lupas, . The major form has an observed molecular mass of 125 -130 kDa. A shorter form is observed in more stringent conditions of cell lysis and may represent a protein strongly associated with a cell component or a degradation product. We studied the expression of the TACC1 gene in human cancer. We found that TACC1 mRNA is underexpressed in several types of cancers. We further showed that TACC1 mRNA and TACC1 protein are underexpressed in a good proportion of breast tumors. When present, the TACC1 protein is localized largely in the cytoplasm of tumor cells. We and others (Dhanasekaran et al., 2001) have also observed downregulation of TACC1 mRNA respectively in breast and prostate tumors using cDNA arrays (Dhanasekaran et al., 2001; Bertucci et al., 2002) .
There have been conflicting results regarding the status of TACC genes in human cancers. The first member of the family was attributed a cell transforming capacity (Still et al., 1999a) , TACC2 was in contrast viewed as a tumor suppressor gene (Chen et al., 2000) and TACC3 was suspected to act as an oncogene (Still et al., 1999b) . It is frequent that different members of families of genes have contrasting activities, and may even antagonize each other. Another explanation has been proposed by Gergely et al. (2000b) who investigated the function of the D-TACC protein in the regulation of the interactions between centrosomes and microtubules: it has been proposed that, because an exquisite control is required in this sensitive area, either an increase or a decrease of TACC activity could have deleterious effects on genetic stability. This would explain how TACC1 may be transforming when overexpressed and in the same time down-regulated in human cancers. The TACC1 gene is located in a region where several cancer genes are suspected to be located (Ade´laı¨de et al., 1998; Ugolini et al., 1999) . TACC1 may be one of the suspected TSG. Further work will be necessary to determine the mechanism leading to the alteration of TACC1 expression. As a preliminary analysis, we did a search for loss of heterozygosity (LOH) at microsatellite (CA) n markers of the 8p11 -21 chromosomal region in microdissected breast tumor samples. The frequency of LOH at D8S1821 (5' of TACC1) and D8S255 (3' of TACC1) was high but not the highest (not shown). This suggests that deletion may be one mechanism of TACC1 inactivation; other genes in the vicinity of TACC1 may be more frequently altered in breast cancer.
The potential normal function of TACC1: the RNA connection
To better understand the potential role of TACC1 in cancer, we initiated a study of its normal cell function. We searched for potential protein partners of TACC1 using the two-hybrid system in yeast and isolated the LSM7 and SmG proteins. The interaction between TACC1 and LSM7 was confirmed by biochemical tests. LSM7 and SmG belong to a class of small proteins with Sm motifs that are highly conserved from yeast to mammals and associate with the U1-U6 snRNAs to form the snRNPs. There are eight ubiquitous Sm proteins (SmB, B2, D1-D3, E, F, G); they associate with U1, U2, U4 and U5. There are 10 LSM proteins (LSM1 -10) in humans; they specifically associate with U6 snRNA and with mRNA; they thus play a role in several aspects of mRNA processing; in particular they activate mRNA decapping and degradation, and function in pre-mRNA splicing Mitchell and Tollervey, 2000 , for reviews). The Sm and LSM related families assemble in two distinct seven-member ring complexes (SalgadoGarrido et al., 1999) . The Sm and LSM proteins shuttle from the cytoplasm to the nucleus to ensure their functions. A phylogenetic tree (Figure 7 ) of the LSM/Sm protein families showed that LSM7 and SNRPG/SmG, and their respective orthologs CG13277 and CG9742, constitutes a subfamily and share a common ancestor (7/G) that separated from other ancestors (i.e. 2/D1, 3/D2, 4/D3, 5/E, 6/F). There are no recorded mutant alleles of CG13277 and CG9742 (http://flybase.bio.indiana.edu:82/). It is possible that different TACC proteins associate with members of distinct Sm subfamilies. We cannot exclude that TACC1 does not interact with other Sm or Smlike proteins. It will also be interesting to see if D-TACC interacts with any of the Drosophila Sm orthologs.
The interaction of TACC1 with LSM7 and SmG points to a role of TACC1 in the control of mRNA metabolism. This role has been demonstrated in Xenopus. In this animal, Maskin, the TACC3 ortholog, associates with the 3'UTR-CPE binding protein (CPEB) to repress eIF-4E control of translation and oocyte maturation (Stebbins-Boaz et al., 1999; Mendez and Richter, 2001 ). CPEB and Maskin are present on the mitotic apparatus of animal pole blastomeres in embryos (Groisman et al., 2000) . Our results show that human TACC1 also associates with regulators of mRNA processings. The role of TACC1 in this regulation will need to be better precised. Our study suggests that alteration of TACC1 function in mRNA metabolism may have important consequences in cell behavior and may participate in carcinogenesis events. Indeed, an Sm-like protein, CaSm/LSM1, has been shown to contribute to the transformed state of pancreatic cells (Schweinfest et al., 1997) , and CaSM antisense therapy has been shown to reduce tumor pancreatic growth (Kelley et al., 2000) .
Several important studies have shown that TACC proteins interact with centrosomes and microtubules in various ways (Gergely et al., 2000a,b; Cullen and Ohkura, 2001 ); TACC1 proteins are only weakly concentrated at centrosomes, and only during mitosis; when overexpressed TACC1 proteins are uniformly distributed in the cytoplasm during interphase and form ordered structures that cluster around the nucleus (Gergely et al., 2000a) . In Drosophila and in humans, msps (mini spindles) and the human ortholog of msps, a microtubule-associated protein called ch-TOG (Charasse et al., 1995 (Charasse et al., , 1998 Charrasse and Larroque, 2000) have been identified as interactors of the D-TACC and TACC3 protein respectively (Cullen and Ohkura, 2001; Lee et al., 2001) . It has been reported recently that ch-TOG interacts with human TACC1 in a two-hybrid screen (Lauffart et al., 2002) . In fly, protein complexes with D-TACC include the aurora kinase (Giet and Prigent, 1999) , which phosphorylates D-TACC (Giet et al., 2002) . Human Aurora A/STK6 coimmunoprecipitates with TACC3 (Giet et al., 2002) . Some of the interactions of TACC proteins with their partners are likely to be regulated by phosphorylations. We have shown here that TACC1l can be phosphorylated.
Our current hypothesis is that TACC proteins regulate mRNA processing by participating in complexes of proteins that are localized in specialized areas (including the centrosomes) in which specific proteins are being locally produced (Kloc et al., 2002) . These proteins include Cyclin B1, which controls entry in mitosis and whose mRNA and protein are concentrated together with Maskin/TACC3 on centrosomes and spindles (Groisman et al., 2000; Richter, 2001) . TACC proteins, regulated by mitotic kinases (Glover et al., 1998; Giet and Prigent, 1999) , may help coordinate microtubule-associated events involved in the control of mitosis, in particular the G2/M checkpoint. This critical step is highly regulated and loss of function of TACC3 triggers p53-mediated apoptosis (Piekorz et al., 2002) . The role of TACC/ Maskin might extend to the control of mRNAs en route along the microtubule tracks, to specialized areas in polarized cells (Richter, 2001) , in the RNA granule (Carson et al., 1998) . Whether the precise role of TACC1 is similar or is involved in a different aspect of mRNA control will have to be determined. A central position at specific sites and crucial function in cell cycle and/or cell polarity would endow TACC proteins with potential carcinogenic capacity. In cancer, there would be a release of TACC control on mRNAs coding for proteins involved in cell division and polarity, leading to abnormal mitotic daughter cells and/or defects in polarity. Alteration of the regulation of mRNA metabolism represents a possible important mechanism of carcinogenesis of which there remains much to discover (Clemens and Bommer, 1999).
Materials and methods
Oligonucleotide primers
The following primers were used: sense primer: TACC1S6: 5'-CGGGGATCCATGGCGTTCAGCCCGTGGCA-3' (nucleotides 320 -340 in the AF049910 TACC1 sequence); antisense primers: TACC1AS6: 5'-GGATTCGGGGAGAGGTGTG-CCCTCCACAG-3' (1078 -1100); TACC1AS2: 5'-AAAGC-GGGACAGGCAGCAGTAG-3' (2891 -2867); TACC1AS1: 5'-CTAGACTATGCAACCCTCTAGGG-3' (2963 -2940); TACC1AS0: 5'-CAAACTCAGCAGCCTAAGGGAACCTT-CATAG-3' (3021 -2982).
Cloning of TACC1 cDNAs
Two different experiments of 5' RACE PCR were necessary to obtain the coding sequences of TACC1 by using a Marathon cDNA amplification kit (Clontech, Palo Alto, CA, USA). First, a 1.9 kb TACC1 cDNA fragment (nucleotides 933 to 2867 bp in the AF049910 TACC1 sequence) was amplified as follows: first-strand cDNA was synthetized from 2 mg of total RNA from the Burkitt's lymphoma DAUDI cell line by using the specific TACC1AS0 primer; second-strand cDNA was synthetized and adapterligated according to the manufacturer's protocol: a firstround of PCR using the TACC1AS1 primer and the adapter primer AP1 from the Marathon kit (35 cycles with denaturation at 948C (30 s), annealing at 658C (30 s), and elongation at 688C (4 min) using the Advantage TAQ polymerase (Clontech). One tenth of the PCR product was reamplified with a nested-specific TACC1 primer (TACC1AS2) and the adapter primer AP2. PCR conditions were the same as for the first-round amplification. The second-round PCR product was purified by using Nucleospin extract kit (Macherey-Nagel, Du¨ren, Germany) and subcloned into the pGMTe (Promega, Madison, USA), and sequenced by Genome Express (Meylan, France). Second, to obtain the 5' part of TACC1 cDNA, the single-strand cDNA was obtained from 2 mg of PolyA + RNA from normal breast (Clontech) using random hexanucleotides. Second-strand was obtained using the specific primers TACC1S6 and TACC1AS6. PCR conditions were as follows: 35 cycles with denaturation at 948C (30 s), annealing at 658C (30 s), and elongation at 728C (1 min) using the TAQ DNA polymerase (Life Technologies). Subcloning of the cDNA fragment, and sequencing were done as described above. The full-length coding cDNA (TACC1-long: TACC1l) was reconstructed from the two fragments by using the StuI enzymatic site localized at nucleotide 939 of the TACC1 sequence. The TACC1l sequence was then subcloned in pCDNA-3 tagged HA in 5' and in pBTM116 vector. A 1516-kb fragment corresponding to a spliced TACC1 isoform (TACC1-short: TACC1s) was inserted in XbaI/HindIII sites of pRK5 tagged myc in 5'.
TACC1 genomic structure
The genomic structure of the gene was deduced based on sequence comparison of the cDNA sequence of TACC1 (AF049910) with Homo sapiens genomic contig sequence at http://www.ncbi.nlm.nih.gov/genome/seq/HsBlast.html. Briefly, in BLAST searches of genome sequence databases (Altschul et al., 1997) , the coding region of TACC1 identified a genomic sequence from the working draft sequence fragment AC067817 (gi:13959300 at http://www.ncbi.nlm.nih.gov:80/ cgi-bin/Entrez/hum_srch?chr=hum_chr.inf&query) composed Figure 7 Phylogenetic tree of human and Drosophila Sm-like proteins. Sm domains of Sm and LSM proteins were used for alignments. The tree is unrooted. Each human Sm protein and each LSM protein have an ortholog in fly but not all Drosophila orthologs are shown. LSM7 and SNRPG/SmG, the two identified interactors of human TACC1, constitutes a subfamily (see also Salgado-Garrido et al., 1999) . Bootstrap values (out of 1000 replicates) are indicated at each node TACC1 in breast cancer N Conte et al of 28 unordered pieces. Alignment of these overlapping pieces with the cDNA sequence allowed to determine the genomic organization of the TACC1 gene.
Cell lines
HeLa cell line and breast carcinoma cell lines BT-20, MCF7, MCF10F, MDA-MB-134, MDA-MB-157, MDA-MB-175, MDA-MB-231, MDA-MB-453, CAMA-1, HCC1395, HCC1569, HCC1806, HCC1937, SK-BR-7, T47D, UACC-812, and ZR-75-1, and breast epithelial cell line HBL-100 were purchased from the American Type Culture Collection (http://www.atcc.org/). The HME-1 cell line was purchased from Clontech. The BrCa-Mz-02 cell line is a gift from Dr V Mo¨bus (Ulm, Germany) and the SUM-102, SUM-149, SUM-185 cell lines a gift from Dr S Ethier (Michigan, USA; http:// www.cancer.med.umich.edu/breast_cell/clines/clines.html). All these cells were grown as recommended. Cos-1 cells were maintained in Dulbecco's modified Eagle's medium with 10% newborn serum. All cells were cultured in a 5% CO 2 incubator at 378C.
Patient material, clinicopathologic and statistical analyses
Tumors were collected at Institut Paoli-Calmettes (Marseille, France) and flash frozen in liquid nitrogen. All samples were reviewed by two independent pathologists, and classified according to the WHO recommendation. The series of 61 tumors were tested in Northern blot including 44 ductal invasive, 12 lobular invasive, two medullary carcinomas, three mixed ductal and lobular carcinomas.
The series of 57 tumors tested in tissue microarray contained 45 ductal invasive, four lobular invasive, three medullary and five mixed ductal and lobular carcinomas. The median age of the patients was 53. A series of 48 consecutive breast carcinoma samples were tested in whole section immunohistochemistry, including 38 ductal invasive (31 of common type, four tubular, two with predominant intraductal component, one mucinous), seven lobular invasive, three mixed ductal and lobular carcinomas. The median age of the patients was 57 years. The clinical data and follow-up of the women included in the study were obtained from medical records. The following clinical and histopathological parameters were analysed: menopausal status, histological tumor size, axillary lymph node status, histologic grade, proliferation index (Ki-67 evaluation), P53 and ERBB2 immunohistochemistry. Statistical analysis was done by w 2 or Fisher exact test.
RNA analysis
The multiple-tissue human Northern blots (Clontech, Palo Alto, CA, USA; number 7759-1, 7760-1, and 7767-1) were hybridized according to the manufacturer's instructions. RNAs from tumor samples were isolated from frozen tissue samples by the guanidine isothiocyanate method. Ten mg of each total RNA were subjected to electrophoresis in 1% agarose/10% formaldehyde gels, and transferred onto biotrans membranes (ICN, CA, USA). Hybridizations were done according to Church and Gilbert (1984) with a 32 Plabeled TACC1 probe (Megaprime kit RPN-1607, Amersham-Pharmacia Biotech, Buckinghamshire, UK) corresponding to a 827-bp EcoRI/NotI fragment from zdl18D05 cDNA clone (from 6911 to 7738 bp in the TACC1 sequence). The b actin probe was purchased from Clontech. The filters were washed at high stringency and imaged using a phosphoimager. Differential expression of TACC1 mRNA between normal breast (RNA purchased from Clontech) and the tumor samples was assessed by scan of the filters in a Fujix Bas 1500 system (Fuji, Tokyo, Japan). The expression results were normalized with RNA 28S. The quantitative analyses of hybridization results were done using a Bioimage software (TINA 2.09, Raytest, Straubenhardt, Germany). Data reports were then exported into a microcomputer and analysed using Excel software (Microsoft). The 'Cancer profiling array' from Clontech (number 7841-1) was hybridized with the same TACC1 probe according to the manufacturer's instructions and the measurements were done as above.
Antibodies
The GPEGDPEEEDSQAETK peptide, corresponding to amino acids 35 -50 of the TACC1 sequence, was chosen for chemical synthesis (Neosystems, Strasbourg, France) owing to its predicted antigenicity. The peptide was coupled to keyhole limpet hemocyanin as hapten, suspended in PBS, and used to immunize rabbits by intramuscular and subcutaneous injections. The antibody generated against the peptide was designed 'anti-TACC1-N'. It was subsequently affinity purified on a Affigel-15 column (BioRad). To obtain anti-SPAZ1 and anti-TACC1-C specific antibodies, the GDARFQKSPPDIKETPY peptide, corresponding to amino acids 280 -295, and the YSDKTAVLTLIREE peptide, corresponding to amino acids 601 -612 of the TACC1 sequence were respectively chosen, and the same procedure was used. The following polyclonal antibodies were used for immunofluorescence, immunoprecipitation and immunoblotting: anti-HA (3F-10, Roche Diagnostics, Meylan, France) and the mouse monoclonal anti-myc 9E10 (Santa Cruz Biotechnology). A commercial anti-TACC1 (Euromedex, Mundolsheim, France) was also used for comparative Western immunoblotting experiments.
Immunofluorescence analyses
Hela or Cos-1 cells were grown on coverslips (2610 5 cells/ 60 mm plates) 1 day before transient transfection. Twelve hours after transfection, cells were washed once in PBS and fixed in 3.7% paraformaldehyde in 16PBS for 15 min at room temperature. After extensive washes, cells were permeabilized and blocked in 5% fetal calf serum/PBS, 0.1% Triton X-100 for 20 min. Cells were then incubated with either affinity-purified anti-TACC1-N (dilution, 1 : 100), which gave the best results of all anti-TACC1 antibodies in immunofluorescence, anti-myc (1 mg/ml), or anti-HA (dilution 1 : 1000) antibody for 1 h at room temperature, rinsed several times in 16PBS, and then incubated with 2 mg/ml of the Alexa-conjugated either anti-rabbit or anti-mouse or anti-rat secondary antibody, respectively. Control of the specificity of anti-TACC1-N was done as described above. The DNA was colored by incubation with Syto-16 (Molecular probes Eugene, OR, USA).
Confocal analysis
The three-dimensional immunofluorescence images were recorded by TCS-NT confocal Microscope (LEICA microsystem, Mannheim, Germany). Three-dimensional views of cells were generated as section representation mode with the IMARIS software (BITPLANE AG, Zurich, Switzerland). Before this, three-dimensional images restoration was made with an MLE (Maximum Likehood Estimation) iterative deconvolution method using HUYGENS2 software (SVI, BITPLANE AG) on SGI o2 workstation.
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Breast tumor analyses
Tissue microarray analysis It was done as described with slight modifications. Briefly, for each tumor, five representative areas were selected from a hematoxylin-eosin stained section of a donor block; five corresponding cylinders with a diameter of 0.6 mm each were punched from these areas and deposited into a recipient paraffin block using a specific arraying device (Microm, Francheville, France). Five-mm sections of the resulting microarray block were made and used for immunohistochemistry analysis after transfer to glass slides.
Immunohistochemistry Five-mm sections from formalinembedded tissue specimens were deparaffinized in xylene and rehydrated in graded alcohol. Antigen enhancement was done by incubating the sections in Target Retrieval solution (Dako, Copenhagen, Denmark) as recommended. Slides were then transferred to a Techmate 500 automater stainer (Dako).
Staining was performed at room temperature as follows: after washes in phosphate buffer, slides were first incubated with blocking serum (Dako) for 10 min and then with the affinitypurified anti-TACC1-N (dilution, 1 : 100) for 1 h, followed by quenching of endogenous peroxidase activity by treatment with 0.1% H 2 O 2 . After washes, the slides were incubated with biotinylated antibody against rabbit Ig for 20 min followed by streptavidin conjugated peroxydase (DAKO LSAB R 2 kit), counter-stained with hematoxylin, and coverslipped using Aquatex (Merck, Darmstadt, Germany) mounting solution.
In control experiments, TACC1 immunogen peptide (10 mg/ ml) was coincubated with anti-TACC1-N antibody. Slides were evaluated under a light microscope by two pathologists (E Charafe-Jauffret and J Jacquemier).
Two-hybrid procedure
To prepare the baits, proteins were fused to the LexA-BD subunit using pBTM116 vector which carries Trp1. For library screening, an oligo-dT primed human cDNA breast library cloned in pACT2 vector (Clontech) which carries Leu2 as a selection marker was screened by using the LexATACC1l as a bait and the yeast strain L40 following the lithium-acetate protocol. Approximately 130 Trp+Leu+ transformants were selected on plates with supplemented minimum medium that lacked tryptophan, leucine, histidine in the primary screening and contained 10 mM 3-aminotriazole (3-AT) and then tested for the b-galactosidase activity by the filter method in the secondary screening. After rescue, the DNA of selected clones was retransformed in L40 yeast containing LexA-TACC1l or LexA fused to control proteins. Specific clones were positive for growth in histidine deficient medium and b-galactosidase activity. LSM7 and SmG pACT2 clones were subcloned in pRK5 tagged myc vector for biochemical studies and in PGEX-Tag vector for the production of all GST fusion proteins.
Biochemical procedures
Protein procedures Cells were washed twice with cold PBS and lysed either in RIPA buffer (150 mM NaCl, 1% Nonidet P-40 (NP40), 0.5% deoxycholate, 0.1% SDS and 50 mM TrisHCl pH 8.0) or in NP40 lysis buffer (20 mM Tris, HCl pH 7.4, 50 mM NaF, 150 mM NaCl, 1% NP40, 1 mM NaVO4, 1 mM EDTA) supplemented with 1 mM phenylmethylsulfonylfluoride, 10 mg.ml 71 aprotinin and 10 mg.ml 71 leupeptin. After centrifugation at 16 000 g for 10 min, lysate protein content was normalized using the BioRad protein assay kit. For immunoprecipitation, lysates were incubated with antibodies overnight at 48C. Protein A-agarose was added and immune complexes bound to beads were recovered after 1 h, washed three times with lysis buffer described above and boiled in 16 sample buffer.
Immunoblotting analysis Cell extracts were boiled in reducing buffer for 5 min and protein were loaded onto 7.5% acrylamide gels. Gels were transferred onto an Nitrocellulose membrane (Amerscham, Life science) at 30 V for 18 h using a transblot apparatus (BioRad). Residual binding sites were blocked by membrane incubation in PBS-5% dry milk solution (Eurobio, France) for 2 h at room temperature. After incubation with anti-TACC1-N, anti-SPAZ1 (dilution: 1 : 300 in TBS-5% dry milk) for 1 1 2 h, or commercial anti-TACC1 (1 : 1000) overnight, filters were washed in TBS-Tween 0.05%. Peroxidase labeled anti rabbit serum preformed complex (Jackson ImmunoResearch, USA) was then added (dilution: 1 : 10 000 in TBS-5% dry milk) and incubation was done at room temperature for 45 min. After several washings in TBS-Tween 0.05%, filters were reacted 1 min with chemiluminescent substrate luminol (ECL kit; Amersham) and revealed by brief exposure using autoradiography films (Kodak, XO Mat AR).
GST pull-down assays GST fusion proteins were expressed by standard techniques (Batzer et al., 1994) . Lysates were incubated with GST fusion proteins bound to glutathione agarose beads for 2 h at 48C. The beads were then washed three times with lysis buffer, boiled in 16 sample buffer, and separated by SDS -PAGE. In all experiments, the presence of comparable amount of GST was verified by Ponceau staining of the membrane.
In vitro kinase assay Cos-1 cells transfected with either TACC1l or TACC1s were rinsed twice in PBS and lysed in 500 ml NP40 lysis buffer supplemented with 1 mM PMSF and 1 mM Na orthovanadate. Cell lysates were incubated with anti-TACC1-C antibody for 2 h, then protein A-Sepharose was added. Immune complexes were washed three times with lysis buffer and twice with WASH buffer (50 mm Tris pH 7.5, 1% NP40, 1 mM Na orthovanadate). Pellets were resuspended in 10 ml KRB (WASH buffer supplemented with 10 mM MnCl 2 ) and incubated for 15 min at 308C with 0.15 mCi [g-32 P]ATP (NEN, Les Ulis, France). The reaction was stopped with cold lysis buffer and the pellets were resuspended in 36 sample buffer. Precipitated proteins were resolved by 7.5% acrylamide gel. The gel was then dried and exposed to Kodak XAR film.
Phylogenetic analysis
A phylogenetic tree with human (http://www.ncbi.nlm.nih.-gov/LocusLink/) and Drosophila (http://hedgehog.lbl.gov: 8001/cgi-bin/annot/query) sequences was constructed using the distance matrix (Blosum 30 matrix) and neighbor-joining algorithms implemented in Clustal W. A total of 1000 bootstrapped replicates were run.
